Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23064603 | 1.00 | KHK (0.48) | KHKKDM1A | |
| SCHEMBL5530870 | 1.00 | KHK (0.48) | KHKKDM1A | |
| SCHEMBL28791101 | 0.95 | KHK (0.44) | KHKKDM1A | |
| Acetic Acid SCHEMBL27852945 | 0.86 | SLC6A3 (0.52) | KHK | |
| SCHEMBL28027328 | 0.82 | KHK (0.41) | KHK | |
| SCHEMBL22852305 | 0.82 | KHK (0.41) | KHK | |
| SCHEMBL14178970 | 0.81 | KDM1A (0.46) | KDM1A | |
| SCHEMBL4809330 | 0.81 | KDM1A (0.46) | KDM1A | |
| SCHEMBL4813568 | 0.81 | KDM1A (0.46) | KDM1A | |
| SCHEMBL27335607 | 0.81 | KDM4E (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4545515-A1 | BCL-2 INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-04-30 | — | — | EP | disclosed |
| US-20240376104-A1 | Bcl-2 Inhibitors | BEIGENE LTD. (KY) | 2024-11-14 | — | — | US | disclosed |
| US-12077536-B2 | BCL-2 inhibitors | BEIGENE, LTD. (KY) | 2024-09-03 | — | — | US | disclosed |
| CN-117683029-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117430601-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-112437772-B | Bcl-2 inhibitors | 百济神州有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
| US-11420968-B2 | Bcl-2 inhibitors | BEIGENE, LTD. (KY) | 2022-08-23 | — | — | US | disclosed |
| EP-3788042-A1 | BCL-2 INHIBITORS | BeiGene, Ltd. (KY) | 2021-03-10 | — | — | EP | disclosed |
| CN-112437772-A | Bcl-2 inhibitors | 百济神州有限公司 | 2021-03-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | KHK 3809/4885KDM1A 2400/4885 |
| US-11420968-B2 | Bcl-2 inhibitors | BCL2, BCL2L1, BCL2L2 | KHK 3809/4885KDM1A 2400/4885 |
| US-12077536-B2 | BCL-2 inhibitors | BCL2, BCL2L1, BCL2L2 | KHK 3809/4885KDM1A 2400/4885 |
| US-20240376104-A1 | Bcl-2 Inhibitors | BCL2, BCL2L1, BCL2L2 | KHK 3809/4885KDM1A 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.